Southern Illinois University School of Medicine

ADDRESS:

Center for Alzheimer Disease and Related Disorders
Department of Neurology
Southern Illinois University School of Medicine
751 N Rutledge Street, Room 3100
Springfield, Illinois 62702
Work Phone: (217) 545-7881
FAX: (217) 545-1903
e-mail: tala@siumed.edu

PERSONAL: Birthdate: March 25, 1948

CURRENT RESEARCH: Clinical and neuropathological research in Alzheimer's disease, dementia with Lewy bodies, vascular dementia, and other dementing illnesses. Clinical evaluation of new drugs to treat Alzheimer's disease.

APPOINTMENTS:
1999 to date: Associate Professor of Clinical Neurology, Southern Illinois University, Springfield, IL.
1987-1999: Active Staff, Department of Neurology, Regions Hospital, St. Paul, MN.
1991-1999: Assistant Professor, Department of Neurology, University of Minnesota, Minneapolis, MN.
1997-1999: Courtesy Staff, HealthEast Medical Staff, St. John's Northeast Hospital, Maplewood, MN.
1988-1996: Acting Director, Memory Disorder Clinic, Regions Hospital, St. Paul, MN.
1987-1991: Instructor, Department of Neurology, University of Minnesota, Minneapolis, MN.

EDUCATION:
1985-1987: Research Fellow, Alzheimer's Treatment and Research Center, Regions Hospital, St. Paul, MN.
1982-1985: Neurology residency, University of Minnesota, Minneapolis, MN.
1981-1982: Flexible internship, Hennepin County Medical Center, Minneapolis, MN.
1978-1981: MD degree, University of Minnesota, Minneapolis, MN.
1966-1970: BS degree in Chemical Engineering, Michigan Technological University, Houghton, MI.

HONORS: AOA honorary fraternity, University of Minnesota Medical School. 1970 salutatorian and several honorary fraternities, Michigan Technological University.

MEDICAL LICENSURE: Illinois #036-101302, 1999; Minnesota #029723-7, 1985-2000.
BOARD CERTIFICATION: American Board of Psychiatry and Neurology, #28679, 1986.

COMMUNITY SERVICE AND HOBBIES: Young Life, nature photography, music composition.

OTHER PROFESSIONAL EXPERIENCE:
1993-1999: Neurological consultant to the Minnesota Board of Medical Practice.
1985-1989: Associate Staff, Dept. of Neurology, Mercy Medical Center, Coon Rapids, MN.
1985-1989: Associate Staff, Dept. of Neurology, North Memorial Medical Center, Robbinsdale, MN.
1970-1978: Technical Service Engineer, 3M Co., St. Paul, MN. Conducted research in lithographic chemistry and field-tested a novel lithographic platemaking system for the newspaper industry.
1969: Development Assistant, Parke-Davis Co., Holland, MI (summer employment).
1968: Engineering Assistant, Panhandle Eastern Pipeline Co., Kansas City, MO (summer employment).

COMMITTEES:
2001-date: SIU Information Management Policy Committee.
1993-1999: GRECC Local Advisory Committee, VA Medical Center, Minneapolis.
1994-1999: Univ. of Minn. Medical Student Neurology Externship Program, Course Site Coordinator.
1997-1999: Medical and Scientific Council for the Minnesota Lakes Chapter of the Alzheimer's Assoc.
1994-1995: Regions Hospital, Surgical Intensive Care Unit Committee.
1988-1994: Alzheimer's Advisory Board, University Health Care Center, Minneapolis.
1990-1992: Ramsey Clinic Nominating and Review Committee.
1988-1990: Regions Hospital, Medical Records Committee.

AD HOC JOURNAL REVIEWER: Pharmaceutical Research 1992; Neuroscience Letters 2001; Journal of Neuropsychiatry and Clinical Neurosciences 2001; BioMed Central 2001.

MEMBERSHIPS: Alzheimer's Association, American Academy of Neurology, American Medical Association, Illinois State Medical Society, Sangamon County Medical Society

GRANTS:
1998, 1999: Ramsey Foundation: "Can thioltransferase reverse free radical damage to the human brain muscarininc receptor?," with Dr. William H. Frey; $25,000 per year.

1998: Ramsey Foundation: "Arachidonic acid inhibition of the muscarinic receptor," with Dr. William H. Frey; $25,000.

1994, 1995, 1996, 1997: Ramsey Foundation: "A peptide in Alzheimer's brain inhibits antagonist binding to the muscarinic cholinergic receptor," with Dr. William H. Frey; $20,000 per year (94-96), $25,000 (97).

1992, 1994, 1995, 1996, 1997: Ramsey Foundation: "Delivery of nerve growth factor to the brain via the olfactory pathway," with Dr. William H. Frey; $20,000 per year (92-95), $25,000 per year (96, 97).

1989: Ramsey Foundation: "Nutrition in Alzheimer's disease," with Dr. Edward Ratner; $20,000.

1986: Ramsey Foundation: "A blood test for Alzheimer's disease," with Drs. Bruce D. Snyder and William H. Frey; $20,000.

PUBLICATIONS:

Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. Int J Ger Psychiatry. 2002;17:503-509.

Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;70:483-488.

Ala TA, Yang K-H, Sung JH, Frey WH II. Inconsistency between severe substantia nigra degeneration with Lewy bodies and clinical parkinsonism in dementia patients. Acta Neuropathol (Berl). 2000;99:511-516.

Ala TA, Beh GO, Frey WH II. Pure hippocampal sclerosis. A rare cause of dementia mimicking Alzheimer's disease. Neurology. 2000;54:843-848.

Ala TA, Yang K-H, Sung JH, Frey WH II. Clinical parkinsonism in dementia patients with substantia nigra Lewy bodies. J Neural Transm. 1999;106:46-57.

Chen X-Q, Fawcett JR, Rahman Y-E, Ala TA, Frey WH II. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alz Dis. 1998;1:35-44.

Kjome JR, Swenson KA, Johnson MN, Bordayo EZ, Anderson LE, Klevan LC, Fraticelli AI, Aldrich SL, Fawcett JR, Venters HD Jr, Ala TA, Frey WH II. Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acid. J Mol Neurosci. 1998;10:209-218.

Ala TA, Yang K-H, Sung JH, Frey WH II. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at time of presentation: a clinicopathologic study. J Neurol Neurosurg Psychiatry. 1997;62:16-21.

Frey WH II, Liu J, Chen X, Thorne RG, Ala TA, Rahman Y-E. Delivery of 125I-NGF to the brain via the olfactory route. Drug Delivery. 1997;4:87-92.

Venters HD Jr, Ala TA, Frey WH II. Inhibition of antagonist binding to the human brain muscarinic receptor by vanadium compounds. Recep Signal Transduct. 1997;7:137-142.

Venters HD Jr, Bonilla LE, Jensen T, Garner HP, Bordayo EZ, Najarian MN, Ala TA, Mason RP, Frey WH II. Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation. Brain Res. 1997;764:93-100.

Frey WH II, Najarian MM, Kumar KS, Emory CR, Menning PM, Frank JC, Johnson MN, Ala TA. Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. Brain Res. 1996;714:87-94.

Ala TA, Frey WH II. Validation of the NINCDS-ADRDA criteria regarding gait in the clinical diagnosis of Alzheimer's disease: a clinicopathologic study. Alz Dis Assoc Dis. 1995;9:152-9.

Thorne RG, Emory CR, Ala TA, Frey WH II. Quantitative assessment of protein transport to the rat olfactory bulb following intranasal administration: implications for drug delivery. Brain Res. 1995;692:278-82.

Ala TA, Perfetti PA, Frey WH II. Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurologic symptoms. J Neuroimmunol. 1994;53:109-13.

Chao CC, Ala TA, Hu S, Crossley KB, Sherman RE, Peterson PK, Frey WH II. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol. 1994;1:433-6.

Chao CC, Hu S, Frey WH II, Ala TA, Tourtellotte WW, Peterson PK. Transforming growth factor ß in Alzheimer's disease. Clin Diagn Lab Immunol. 1994;1:109-10.

Frey WH II, Emory CR, Wiebenga ME, Saxena S, Cardelli D, Ala TA, Tollefson GD. Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain. Brain Res. 1994;655:153-60.

Frey WH II, Schmalz JW, Perfetti PA, Norris TL, Emory CR, Ala TA. Silica-ELISA method improves detection and quantitation of minor glycolipid components in lipid mixtures and of other antigens. J Immunol Methods. 1993;164:275-83.

Mendez MF, Ala TA, Underwood KL. Development of scoring criteria for the Clock Drawing Task in Alzheimer's disease. J Am Geriatr Soc. 1992;40:1095-9.

Ala T, Romero S, Knight F, Feldt K, Frey WH II. GM-1 treatment of Alzheimer's disease: a pilot study of safety and efficacy. Arch Neurol. 1990;47:1126-30.

Ala T, Romero S, Knight F, Frey WH II. GM-1 treatment of Alzheimer's disease. In: Wurtman RJ, Corkin SH, Growden JH, and Ritter-Walker E, eds. Alzheimer's Disease: Advances in Basic Research and Therapies. Cambridge, MA: Center for Brain Sciences and Metabolism Charitable Trust; 1989;621-7.

Frey WH II, Ala TA. Recent advances in Alzheimer's disease research. Progress in Clinical Neurosciences. 1988;1:287-303.

Frey WH II, Emory CR, Madsen AM, Rustan TD, Ala TA. Alzheimer's neurofibrillary tangles are labelled by ganglioside monoclonal antibody A2B5. In: Wurtman RJ, Corkin SH, and Growden JH, eds. Alzheimer's Disease: Advances in Basic Research and Therapies. Cambridge, MA: Center for Brain Sciences and Metabolism Charitable Trust; 1987;411-5.

Emory CR, Ala TA, Frey WH II. Ganglioside monoclonal antibody (A2B5) labels Alzheimer's neurofibrillary tangles (NFT). Neurology. 1987;37:768-72.

ABSTRACTS AND LETTERS:

Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. The Mini-Mental State examination may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. In: Programme Book of the 17th International Conference. Christchurch, New Zealand: Alzheimer's Disease International; 2001:149 (Abstract).
Ala TA. Orientation agnosia in pentagon copying. J Neurol Neurosurg Psychiatry. 2002;72:129-30 (Reply to Editor).

Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. The Mini-Mental State exam may help in the differentiation of Alzheimer and Lewy body dementias. In: Ageing Myths, Realities & Management of Alzheimer's Disease. An International (Mini)Symposium to the Millennium 52nd Indian Pharmaceutical Congress. Hyderabad, India: Indian Pharmaceutical Association; 2000:3 (Abstract).

Ala TA, Beh GO, Frey WH II. Hippocampal sclerosis: a rare cause of dementia in the elderly mimicking Alzheimer's disease. Neurology. 2000;55:739-740 (Reply to Editor).

Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ. Patients with Lewy body dementia draw the interlocking pentagons on the Mini-Mental State examination less accurately than patients with Alzheimer disease: a cliniconeuropathological study. Neurobiol Aging. 2000;21:S83 (Abstract).

Ala TA, Beh GO, Frey WH II. Hippocampal sclerosis: a rare cause of dementia in the elderly mimicking Alzheimer's disease. Neurology. 1999;52(Suppl 2):A477 (Abstract).

Ala TA, Frey WH II. A study of white matter pallor as a possible cause of dementia. Neurobiol Aging. 1998;19:S233 (Abstract).

Ala TA, Frey WH II. The prevalence of multi-infarct dementia dementia in patients clinically diagnosed as having Alzheimer's disease: a clinicopathologic study. Neurology. 1998;50(Suppl 4):A408 (Abstract).

Ala TA, Yang K-H, Sung JH, Frey WH II. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at time of presentation: a clinicopathologic study. Focus on Parkinson's Disease. 1998;10:82 (Abstract).

Bordayo EZ, Lagalwar S, Swenson KA, Anderson L, Klevan LC, Fawcett JR, Ala TA, Frey WH II. Effects of arachidonic acid, carotenoids and cannabinoids on the muscarinic receptor. FASEB J. 1998;12:A151 (Abstract).

Chen X-Q, Fawcett JR, Ala TA, Rahman Y-E, Frey WH II. Olfactory route: a new pathway to deliver nerve growth factor to the brain. Neurobiol Aging. 1998;19:S259 (Abstract).

Mattson MD, Frey WH II, Ala TA. The clinical diagnosis of Alzheimer's disease without the use of CT or MRI scans. a clinicopathologic study. Neurology. 1998;50(Suppl 4):A160 (Abstract).

Thorne RG, Wilson SJ, Fawcett JR, Ala TA, Frey WH II. Delivery of insulin-like growth factor-1 (IGF-1) to the brain via the olfactory pathway: a possible therapeutic strategy for Alzheimer's disease (AD). Neurobiol Aging. 1998;19:S260 (Abstract).

Ala TA, Yang K-H, Sung JH, Frey WH II. The majority of dementia patients with the pathological findings of Parkinson's disease at autopsy do not present with parkinsonian symptoms or signs and are not treated for Parkinson's disease during their course. Neurology. 1997;48(Suppl 2):A104 (Abstract).

Frey WH II, Kjome J, Swenson K, Johnson M, Venters HD Jr, Ala,TA. Inhibition of antagonist binding to the human brain muscarinic receptor by arachidonic acid. FASEB J. 1997;11:A919 (Abstract).

Ala TA, Frey WH II, Clark HB. Posterior cortical atrophy; neuropathologic correlations. Neurology. 1996;53:958 (Letter to Editor).

Ala TA, Yang K-H, Sung JH, Frey WH II. Hallucinations and signs of Parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at time of presentation. Neurobiol Aging. 1996;17:S28 (Abstract).

Fawcett JR, Chen XQ, Rahman Y-E, Ala TA, Frey WH II. Delivery of NGF to the brain via the olfactory route. Mol Biol Cell. 1996;7S:530a (Abstract).

Frey WH II, Venters HD Jr, Bonilla LE, Najarian MM, Ala TA, Mason RP. Heme compounds from Alzheimer's brain inhibit muscarinic receptor binding via thiyl radical generation. Mol Biol Cell. 1996;7S:647a (Abstract).

Venters HJ Jr, Najarian M, Ala TA, Frey WH II. Inhibition of muscarinic receptor binding by pervanadate, orthovanadate, metavanadate and an endogenous inhibitor from Alzheimer's brain. FASEB J. 1996;10:A1285 (Abstract).

Yang K-H, Choi KK, Ala TA, Frey WH II, Sung JH. Neuropathologic analysis of 799 cases of clinically demented patients. Neurobiol Aging. 1996;17:S118 (Abstract).

Frey WH II, Najarian M, Emory C, Ala TA. Oxidized glutathione and endogenous Alzheimer's brain factors inhibit antagonist binding to the muscarinic receptor. FASEB J. 1995;9(4, Part II):A682 (Abstract).

Ala TA, Follmann RK, Frey WH II. Pure multi-infarct dementia rarely mimics Alzheimer's disease throughout its course: a clinicopathologic study. Neurobiol Aging. 1994;15(Suppl 1):S99 (Abstract).

Ala TA, Frey WH II. The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol. 1994;36:455 (Letter to Editor).

Ala TA, Perfetti PA, Frey WH II. Acute elevations of anti-GM1 antibodies may be neurologically asymptomatic. In: Gangliosides and Neural Repair. A Satellite Symposium to the 24th Annual Meeting of the American Society for Neurochemistry. Washington, DC: Fidia Research Foundation; 1993:28 (Abstract).

Ala TA, Tulloch JW, Frey WH II,. Exogenous GM-1 ganglioside may increase auditory P300 latency in Alzheimer's disease. Neurobiol Aging. 1992;13(Suppl 1):S133 (Abstract).

Thorne RG, Perfetti PA, Emory CR, Ala TA, Frey WH II. Quantitative assessment of transneuronal transport to the rat olfactory bulb following intranasal administration of wheat germ agglutinin-horse radish peroxidase (WGA-HRP). Neurobiol Aging. 1992;13(Suppl 1):S132 (Abstract).

Ala T, Romero S, Knight F, Feldt K, Frey WH II. GM-1 treatment of Alzheimer's disease: a pilot study of safety and efficacy. Core Journals in Clinical Neurology. 1991;6:10 (Abstract).

Pascual-Leone A, Dhuna A, Castillo R, Ala T. Displaced Torkildsen's shunt: an unusual cause of cervical myelopathy. J Neurol Neurosurg Psychiatry. 1991;54:654 (Letter to Editor).

Clements JR, Beitz AJ, Emory CR, Ala TA, Romero S, Knight F, Frey WH II. Ganglioside alterations in Alzheimer's disease and treatment of Alzheimer's disease with GM-1. Neurobiol Aging. 1990;11:76 (Abstract).
Mendez MF, Mastri M, Frey WH II, Ala TA. Diagnostic trends in Alzheimer's disease: clinicopathological evidence in 383 cases from the Ramsey Dementia Brain Bank. Neurology. 1990;40(Suppl 1):177 (Abstract).
Ala T, Romero S, Knight F, Frey WH II. GM-1 treatment of Alzheimer's disease. Alz Dis Assoc Dis. 1989;3:3 (Abstract).

Emory CR, Ala TA, Frey WH II. Ganglioside monoclonal antibody (A2B5) labels Alzheimer's neurofibrillary tangles (NFT). Fed Proc. 1986;45:1728 (Abstract).

INVITED PRESENTATIONS:

"An Overview of the Non-Alzheimer's Dementias: How Can We Distinguish Them from Alzheimer's Disease?" Keynote address for the professional education conference of the Greater Illinois Chapter of the Alzheimer's Association. March 1, 2002. Schaumburg, Illinois.

"Dementia with Lewy Bodies: Observations and Diagnosis." Alzheimer's Disease Research Center Tuesday Seminar Series. Washington University. December 6, 2001. St. Louis, Missouri.

"The Mini-Mental State exam may help in the differentiation of Alzheimer and Lewy body dementias." The Millennium 52nd Indian Pharmaceutical Congress. November 30, 2000. Hyderabad, India.

"Dementia." Regina Medical Center CME Conference. June 16, 1999. Hastings, Minnesota.

Respondent for the Citywide Quarterly Geriatric Conference, "Care Strategies for Progressive Dementia." University of Minnesota Center on Aging. August 13, 1998. St. Paul.

"Normal Pressure Hydrocephalus." GRECC Grand Rounds. April 15, 1998. Minneapolis.

"Clinical Aspects of Alzheimer's Disease." American Society for Clinical Laboratory Science Region V Meeting. September 30, 1994. Bloomington, MN.

"Evaluation of Early Dementia." Polk County Medical Society. May 16, 1991. Balsam Lake, WI.
"Judgment and Safety Issues in Alzheimer's Disease." A Geriatric Seminar. Medical Education Committee of Group Health Inc. November 17, 1990. Minneapolis.

"GM-1 Treatment of Alzheimer's Disease." Update on Cognitive Treatment Strategies in Alzheimer's Disease. 42nd Annual Meeting. Gerontological Society of America. November 18, 1989. Minneapolis.
"Congophilic Angiopathy." Neurology Grand Rounds. VA Medical Center. September 23, 1987. Minneapolis.
"Alzheimer's Disease." Annual Convention and Clinical Meeting. Philippine Minnesotan Medical Association. September 12, 1987. Minneapolis.

"Alzheimer's Disease: Clinical Perspective." Basic and Clinical Aspects of Alzheimer's Disease and Epilepsy. Midsummer Mini-symposium. Voyageurs Chapter, Society for Neuroscience. July 15, 1987. Minneapolis.

CLINICAL TRIAL PARTICIPATION:
Galantamine (Reminyl©)

1998-1999: Co-Investigator in "Placebo-controlled evaluation of galantamine in the treatment of Alzheimer's disease: safety and efficacy under a slow-titration regimen," protocol GAL-USA-10, a multi-center trial sponsored by Janssen Research Foundation.

1997-1999: Co-Investigator in "Long-term safety and efficacy of galantamine in the treatment of Alzheimer's disease," protocols GAL-USA-3, GAL-USA-6, and GAL-USA-9, multi-center trials sponsored by Janssen Research Foundation.

1997-1998: Co-Investigator in "Safety and efficacy of galantamine during withdrawal in the treatment of Alzheimer's disease," protocol GAL-USA-5, a multi-center trial sponsored by Janssen Research Foundation.

1997-1998: Co-Investigator in "Galantamine in the treatment of Alzheimer's disease: Flexible dose range trial," protocol GAL-INT-2, a multi-center trial sponsored by Janssen Research Foundation.

1996-1997: Co-Investigator in "Efficacy, tolerability and safety of galantamine in the treatment of Alzheimer's disease," protocol GAL-USA-1, a multi-center trial sponsored by Janssen Research Foundation.

SB 202026

1996-1997: Co-Investigator in "A 48-week double-blind, placebo-controlled, parallel group, fixed dose study of the efficacy, safety and cost-effectiveness of 25µg SB 202026 bid in patients suffering from dementia of the probable Alzheimer's type," sponsored by SmithKline Beecham Pharmaceuticals.

1995-1997: Co-Investigator in "An open label administration of SB 202026 in patients suffering from probable dementia of the Alzheimer's type," sponsored by SmithKline Beecham Pharmaceuticals.

1994-1996: Co-Investigator in "A randomized, double-blind, placebo-controlled, dose-ranging study of the efficacy and tolerability of SB 202026 in patients suffering from dementia of the probable Alzheimer's type," a multi-center trial sponsored by SmithKline Beecham Pharmaceuticals.

Donepezil (Aricept©)

1996-1998: Co-Investigator in "A 54-week, randomized, double-blind, placebo-controlled evaluation of the effects of donepezil hydrochloride (E2020) on functional outcomes in patients with Alzheimer's disease with a staged crossover to open-label donepezil hydrochloride (E2020) treatment," a multi-center trial sponsored by Eisai America, Inc.

Oral physostigmine

1995-1999: Co-Investigator in "The safety and efficacy of long-term administration of extended-release oral physostigmine in Alzheimer's disease and senile dementa of the Alzheimer type," a multi-center open label study sponsored by Forest Laboratories.

1995-1996: Co-Investigator in "The efficacy of extended-release oral physostigmine in Alzheimer's disease and senile dementa of the Alzheimer type," a multi-center trial sponsored by Forest Laboratories.

Sabeluzole

1995-1996: Co-Investigator in "Safety of sabeluzole in the long-tern treatment of Alzheimer's disease: An open label extension study," sponsored by Janssen Pharmaceutical Corporation.

1994-1996: Co-Investigator in "Clinical evaluation of efficacy and safety of sabeluzole in the treatment of Alzheimer's disease," a multi-center trial sponsored by Janssen Pharmaceutical Corporation.

1990-1992: Co-Investigator in "Clinical evaluation of sabeluzole in the treatment of patients with dementia of the Alzheimer type (DAT)," a multi-center trial sponsored by Janssen Pharmaceutical Corporation.
Nimodipine

1991-1999: Co-Investigator in "Nimodipine compassionate use for primary degenerative dementia, program U93-001," sponsored by Miles Pharmaceutical Corporation.

1993-1995: Co-Investigator in "A placebo-controlled, randomized, double-blind, multi-center study of the efficacy and safety of nimodipine (BAY e 9736) in patients with probable Alzheimer's disease," sponsored by Miles Pharmaceutical Corporation.

1989-1991: Co-Investigator in "Phase III study of the efficacy and safety of nimodipine in patients with primary degenerative dementia (PDD)," a multi-center trial sponsored by Miles Pharmaceutical Corporation.

GM-1 Ganglioside

1987-1988: Co-Principal Investigator in "A randomized, parallel group, placebo-controlled double-blind trial of GM-1 (IND #21,435) in mild to moderate Alzheimer's disease," sponsored by Fidia Pharmaceutical Corporation.

TOAST Study (Trial of ORG 10172 in Acute Stroke Treatment)

Albanese MA, Clarke WR, Adams HP Jr, Woolson RF, and the TOAST investigators. Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. the program developed for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Stroke. 1994;25:1746-51.
Davis PH, Clarke WR, Bendixen BH, Adams HP Jr, Woolson RF, Culebras A, and the TOAST investigators. Silent cerebral infarction in patients enrolled in the TOAST Study. Neurology. 1996;46:942-8.

Site designed and maintained by:
Carolyn Higgason - SIU School of Medicine - Department of Neurology
Last Revised 04/11/2008, Copyright © 2006
Privacy Policy